TriSalus Life Sciences, Inc.
TLSI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $200 | $179 | $157 | $133 |
| - Cash | $23 | $26 | $13 | $9 |
| + Debt | $34 | $34 | $33 | $24 |
| Enterprise Value | $212 | $186 | $178 | $148 |
| Revenue | $12 | $11 | $9 | $8 |
| % Growth | 3.1% | 22.3% | 11% | – |
| Gross Profit | $10 | $9 | $8 | $7 |
| % Margin | 83.5% | 83.9% | 83.7% | 85.3% |
| EBITDA | -$9 | -$7 | -$9 | -$9 |
| % Margin | -79.4% | -59.8% | -98.1% | -107.1% |
| Net Income | -$11 | -$8 | -$10 | -$10 |
| % Margin | -93.5% | -73.9% | -113.2% | -122.4% |
| EPS Diluted | -0.96 | -0.27 | -0.39 | -0.41 |
| % Growth | -255.6% | 30.8% | 4.9% | – |
| Operating Cash Flow | -$4 | -$7 | -$4 | -$6 |
| Capital Expenditures | -$0 | $0 | -$1 | -$0 |
| Free Cash Flow | -$4 | -$7 | -$5 | -$6 |